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Latent tuberculosis infection (LTBI) is characterized by the 
presence of immune sensitization to Mycobacterium tuberculo-
sis (MTB) in the absence of any clinical or radiological evidence 
of active disease. The term was coined in 1909 [1], and it has 
since been validated by molecular studies demonstrating reac-
tivation of disease 33 years postexposure [2]. A recent model-
ing study estimated that approximately 1.7 billion people have 
LTBI [3]. Given that LTBI has been recognized for more than 
a century, and that approximately 1 in 4 people worldwide are 
affected, it is perhaps surprising that new data relating to the 
anatomical and cellular niches occupied by MTB during latent 
infection continue to emerge. For much of the 20th century, 
MTB was assumed to be confined to macrophages in quiescent 
granulomas in latently infected individuals. This paradigm has 
subsequently been challenged by findings from necropsy stud-
ies in individuals without signs of active tuberculosis (TB) that 
report the presence of MTB deoxyribonucleic acid (DNA) in 
diverse nonphagocytic cell types within and outside the lung 
[4–6]. Most recently, MTB has been demonstrated in mesenchy-
mal and hematopoietic stem cells [7–10], implicating the bone 
marrow as a previously unappreciated niche for the organism 
in LTBI. In this article, we review the historical and contempo-
rary literature relating to anatomical and cellular locations for 
MTB during latent infection, and we contextualize the presence 
of MTB in stem cell populations within the bone marrow as well 
as in differentiated cell types in multiple tissues for maintenance 
of LTBI in the human host.
ANATOMIC NICHES
Necropsy Studies
The earliest evidence relating to anatomic niches for MTB 
during latent infection comes from historic necropsy studies 
in which macroscopically normal tissue from individuals who 
had died of causes other than TB was inoculated into labora-
tory animals. Findings of these historic studies are summarized 
in Table 1. Material from lymph nodes (thoracic, cervical, mes-
enteric and retroperitoneal) and lung (apices and bases) was 
harvested from autopsies on a total of 628 individuals aged 
from infancy to old age, and MTB was isolated from animals 
inoculated with tissues of 96 individuals (15.3%). Two addi-
tional studies in which tissue from Ghon foci of individuals 
without lesions of active TB were inoculated into laboratory 
animals yielded contrasting results: one study reported the 
presence of MTB in up to 33% of such lesions [11], whereas 
another reported a much lower prevalence of just 1.5% [12]. 
These historic studies have significant methodological limita-
tions: active TB may have been missed in some individuals, 
resulting in an overestimate of the prevalence of cultivable TB 
in latent infection. In contrast, inoculated material might have 
contained small numbers of viable bacilli that did not cause 
disease in laboratory animals, resulting in an underestimate of 
prevalence. These limitations notwithstanding, the studies pre-
sented in Table 1 were the first to indicate that MTB may reside 
in macroscopically normal tissue as well as in Ghon foci. This 
observation paved the way for necropsy studies in the modern 
era that used polymerase chain reaction (PCR) to demonstrate 
presence of MTB DNA (which might equally represent the 
presence of dead or viable bacilli) in diverse cell types in the 
lung, spleen, liver, kidney, and adipose tissue [4–6]; findings 
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from these studies relating to specific cellular niches for MTB 
during latent infection are discussed below.
Transplant-Transmitted Tuberculosis
Additional evidence supporting presence of MTB in the lung, 
liver, and kidney of latently infected individuals comes from 
natural experiments in which tissues from donors with LTBI 
have been transplanted into immunosuppressed recipients. 
Pertinent case reports are summarized in Table  2. Although 
these cannot provide unequivocal proof of disease transmis-
sion from latently infected individuals (because subclinical 
active disease in donors cannot be excluded), they add to the 
body of evidence suggesting wide anatomical distribution of 
MTB in latently infected individuals. Case reports of trans-
mission from solid organ transplants are complemented by 
results of a national survey of TB cases arising in hematopoi-
etic stem cell transplant recipients in Spain [15]: incidence of 
active TB was significantly higher in recipients of allogeneic 
versus autologous transplants. This observation is consistent 
with the hypothesis that hematopoietic stem cells may repre-
sent a niche for MTB during LTBI; equally, it might reflect the 
differential degree of immune compromised status between 
these 2 groups.
Imaging Studies
Further clues relating to the anatomic localization of MTB 
during latent infection come from studies in which individ-
uals with LTBI have undergone positron emission tomogra-
phy-computed tomography (PET-CT) scanning—a functional 
imaging technique that can locate and quantitate uptake of a 
radiolabeled tracer such as 18F-fludeoxyglucose (FDG) by tis-
sues with increased metabolic activity. In one such study, 5 
asymptomatic adults with positive interferon-gamma release 
assay (IGRA) results and normal chest radiographs (human 
immunodeficiency virus [HIV] status not reported) under-
went PET-CT scanning before and 3–4 months after initiation 
of treatment with isoniazid or rifampin [25]. At baseline, 4 of 
5 subjects exhibited increased FDG uptake in hilar, paratra-
cheal, and/or subcarinal lymph nodes—none of which met 
radiologic criteria for enlargement. The FDG uptake by lymph 
nodes was decreased at follow-up in 3 of the 4 individuals 
who exhibited increased uptake at baseline. More recently, 
Esmail et al [26] identified PET-hot lesions in 10 of 35 HIV-
infected adults with a diagnosis of latent TB infection. These 
lesions were located within pulmonary infiltrates and scars, 
and 4 of 10 individuals developed active TB during the fol-
lowing 6 months, suggesting that at least some of these lesions 
may have represented early active TB rather than stable latent 
infection.
Taken together, these studies indicate that MTB has a wide 
anatomical distribution in latently infected individuals, and that 
it may be found in both macroscopically normal and lesional 
tissue, both within and outside the lung. Additional support for 
the concept that MTB may reside at extrapulmonary sites comes 
from studies reporting reactivation of TB at wide anatomical 
locations after biological immunotherapy and HIV infection 
[27–29]. Before reviewing the literature relating to specific 
Table  1. Results of Historical Studies in Which Macroscopically Normal Tissue From Individuals Dying From Causes Other Than Tuberculosis Was 
Inoculated Into Laboratory Animals
Reference Subjects Material Inoculated
Proportion 
Culture-Positive
Loomis 1890, cited in [13] 30 adults Bronchial lymph nodes 8 of 30 (26.7%)
Pizzini 1892, cited in [13] 30 adults Bronchial and cervical lymph nodes 12 of 30 (40.0%)
Kälble 1899, cited in [13] 23 individuals Bronchial lymph nodes 2 of 23 (8.7%)
McFadyean 1903, cited 
in [14]
20 individuals Mesenteric lymph nodes 2 of 20 (10.0%)
Rosenberger 1905, cited 
in [14]
14 adults and children Mesenteric lymph nodes 6 of 14 (42.9%)
Harbitz 1905, cited in [14] 91 children Cervical, tracheal, mesenteric, and retroperitoneal lymph nodes 18 of 91 (19.8%)
Ipsen 1906, cited in [14] 74 children Material included mesenteric lymph nodes 1 of 74 (1.4%)
Bartel 1906, cited in [14] 68 children Cervical, bronchial, and mesenteric lymph nodes 8 of 68 (11.8%)
Weber 1907, cited in [14] 26 children aged 3 months to 12 years Not ascertained 1 of 26 (3.8%)
Beitzke 1912, cited in [14] 27 children Cervical, tracheobronchial, and mesenteric lymph nodes 9 of 27 (33.3%)
Eastwood 1914, cited 
in [14]
61 children Bronchial, mesenteric, and cervical lymph nodes 5 of 61 (8.2%)
Griffith 1914, cited in [14] 34 children Bronchial and mesenteric lymph nodes 2 of 34 (5.9%)
Wang [14] 18 adults and 14 children Cervical, bronchial, mesenteric, and retroperitoneal lymph nodes 3 of 32 (9.4%)
Opie and Aronson [11] 33 adults aged 20–70 years Tissue from lung apices, lung bases, and hilar or tracheobronchial 
lymph nodes of individuals with lesions elsewhere (fibrocaseous 
lesions/scars of apices, caseous encapsulated, or calcified nodes)
15 of 33 (45.5%)
Saenz 1938, cited in [13] 14 individuals Normal lung 1 of 14 (7.15%)
Feldman and Baggenstoss 
[13]
51 adults and children aged 2 to 
93 years, of whom n = 39 had at 
least 1 healed Ghon complex
Tissue from upper and lower lobes of the lung and hilar or tracheo-
bronchial lymph nodes
3 of 51 (5.9%)
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intracellular bacillary niches, we next consider the possibility of 
an extracellular location for MTB during latent infection.
AN EXTRACELLULAR NICHE?
Persistence of extracellular MTB during LTBI is unproven, 
but there is a widely held belief that at least some bacilli may 
survive in extracellular caseous material within granulomas 
during latency, unable to multiply because of the hypoxic and 
proteolytic microenvironment [30]. A  study in mice showed 
that encapsulation of MTB in hollow fibers inserted subcuta-
neously resulted in infiltrating cells forming granulomatous 
lesions around the inserted fibers. Mycobacteria contained 
within the fibers tuned down patterns of gene expression com-
mensurate with active growth and upregulated expression of 
dormancy genes, suggesting that induction of dormancy can 
occur in extracellular organisms [31]. Furthermore, mycobac-
teria are able to use extracellular hyaluronan as a carbon source 
for growth, suggesting that they are able to persist outside host 
cells, at least temporarily [32]. Whether this phenomenon plays 
a role in latency remains to be established. More recent stud-
ies have demonstrated that MTB releases mycobacterial extra-
cellular vesicles that exert diverse effects on the host response, 
including induction of Toll-like receptor (TLR)-2 signaling 
[33]. Although this may augment anti-mycobacterial responses 
in the short term, sustained TLR-2 stimulation may drive 
anti-inflammatory responses and inhibit Th1 polarization of 
CD4+ T cells [34]; such regulatory actions could favor extracel-
lular mycobacterial persistence. MTB-infected neutrophils also 
release extracellular vesicles that activate macrophages and pro-
mote the clearance of intracellular MTB through early superox-
ide anion production and autophagy induction [35].
NICHES IN PROFESSIONAL PHAGOCYTES
Macrophages
The macrophage is the primary intracellular habitat for MTB 
during active disease: it therefore represents an obvious candi-
date as a niche during latency. Understanding the potential role 
of the infected macrophage in latency is complicated by the 
Table 2. Case Reports Documenting Potential Transmission of Tuberculosis From Latently Infected Donors to Immunosuppressed Recipients
Reference Donor Organ(s) Donated Recipients
Ridgeway et al 
[16]
Donor had normal chest radiograph and no known prior history 
of MTB infection or disease
Lung Two separate recipients developed pulmonary TB with 
identical isolate to each other
Graham et al [17] 69-year-old female, died of intracranial hemorrhage, clear chest 
radiograph, no past history of TB
Kidney and liver 
(different 
recipients)
Both recipients developed active TB (renal TB at 
14 months posttransplant in kidney recipient, TB 
osteomyelitis at 12 months posttransplant in liver 
recipient): matching isolates.
Lee et al [18] 51-year-old, nonsmoking, recent immigrant from China, died of 
intracerebral hemorrhage. No previous TB, ante-mortem chest 
x-ray normal, tracheal aspirate smear- and culture-negative for 
acid-fast bacilli.
Lung Developed pulmonary MDR TB at 7 weeks; recipient 
was tuberculin negative pretransplant, with no expo-
sure to MDR-TB.
Boedefeld et al 
[19]
33-year-old male, died of intracranial haemorrhage, emigrated 
from Peru 11 years before. Previous PPD test 24 mm, but 
chemoprophylaxis not given. Chest radiograph normal at time 
of organ donation.
Lung Recipient developed pulmonary and pericardial TB at 
3 months posttransplant; no known TB exposure.
Kumar et al [20] 42-year-old Vietnamese-born male, died of acute intracranial 
hemorrhage. No history of TB or positive TST. Ante- 
mortem CT chest scan showed no pulmonary infiltrates or 
granulomata.
Lung TST-negative recipient developed pulmonary TB at 
3 months posttransplant; isolate of indo-oceanic lin-
eage, associated with Vietnam/Cambodia.
Mortensen et al 
[21]
Male in 20s, died in accident; previous incarceration; clear chest 
radiograph and normal bronchoscopy ante-mortem.
Lung TST-negative recipient developed pulmonary TB at 
2 months posttransplant. MTB isolate matched 
strain from previous outbreak near donor’s home.
Mortensen et al 
[21]
Male in 20s, died in accident; previous travel to Philippines; clear 
chest radiograph, normal bronchoscopy and BAL culture nega-
tive for TB ante-mortem.
Lung Recipient developed PTB at 4 months posttransplant; 
spoligotype “associated with Manila family,” recip-
ient had not traveled outside of the United States.
Jensen et al [22] Donor diagnosed with latent TB 5 years before death after expo-
sure to index case with isoniazid-resistant TB; received inap-
propriate treatment with single agent isoniazid.
Lung Recipient developed pulmonary TB at 11 weeks post-
transplant. MTB isolates from the index case (to 
whom donor was exposed) and transplant recipient 
matched.
Cassir et al [23] 47-year-old male, died of intracranial hemorrhage, no risk 
factors for TB other than chronic alcohol use and smoking. 
TST results unavailable. No signs of active or previous TB on 
ante-mortem CT chest. Pretransplantation lung biopsy culture- 
and PCR-negative for MTB.
Lung 41-year-old female with cystic fibrosis developed pul-
monary TB at 6 weeks posttransplant. No previous 
TB or known TB exposure pre- or posttransplant.
Ruijter et al [24] 57-year-old woman from the Philippines, lethal brain injury. Ante- 
mortem abdominal ultrasound and chest radiography showed 
no abnormalities.
Liver Developed hepatic TB at 6 months posttransplant; 
MTB isolate Manila family.
Abbreviations: BAL, bronchoalveolar lavage; CT, computed tomography; MDR-TB, multidrug-resistant tuberculosis; MTB, Mycobacterium tuberculosis; PCR, polymerase chain reaction; PPD, 
purified protein derivative; PTB, pulmonary tuberculosis; TB, tuberculosis; TST, tuberculosis skin test. 
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fact that 2 distinct macrophage lineages have been described in 
the lung, both of which are infected by MTB: alveolar macro-
phages are derived during embryogenesis from fetal liver and 
are capable of self-renewal at steady state, whereas interstitial 
macrophages are generally thought to arise from blood-de-
rived monocytes at steady state. These ontologically distinct 
populations have been reported to differ in their responses 
to MTB: alveolar macrophages upregulate fatty acid uptake 
and β-oxidation to provide a more nutritionally permissive 
environment for MTB, whereas interstitial macrophages are 
highly glycolytically active to exert nutritional restriction and 
control bacterial growth [36]. Mycobacterium tuberculosis 
itself can influence development of macrophage phenotype: 
Peyron et al [37] used an in vitro granuloma model to show 
that MTB long-chain fatty acids triggered differentiation of 
monocyte-derived macrophages into longer-lived foamy mac-
rophages, characterized by the presence of lipid-containing 
bodies, that exhibited diminished intracellular bactericidal 
activity and harbored intracellular MTB in a dormant, non-
replicative state. These organisms adapted their metabolic 
strategy to use accumulated cytoplasmic lipid bodies, in par-
ticular triacylglycerol, as both carbon and energy sources. This 
metabolic shift was associated with upregulated mycobacterial 
expression of the gene encoding isocitrate lyase, an enzyme 
that is essential for metabolism of fatty acids and persistence 
of MTB in macrophages [38]. Foamy macrophages could 
also provide a long-term niche for dormant MTB by afford-
ing bacilli access to host cholesterol, which is also required 
for mycobacterial persistence [39]. In addition, Singh et  al 
[40] have reported that MTB induces the foamy macrophage 
phenotype, via targeted manipulation of host cellular metab-
olism to divert the glycolytic pathway toward ketone body 
synthesis, which led to perturbations in lipid homeostasis and 
consequent accumulation of lipid bodies in the macrophage. 
Studies of Mycobacterium marinum infection in a zebra fish 
model showed that intracellular mycobacteria can induce 
recruitment of new macrophages to nascent primary granu-
lomas, which then “seed” secondary granulomas via egress of 
infected macrophages [41]. Therefore, macrophages may play 
a key role in systemic dissemination of mycobacteria, as well 
as provide potential niches for bacilli in the lung during latent 
infection.
Dendritic Cells
Using murine infection, Wolf et al [42] showed (1) that up to 
80% of MTB bacilli in the lung and draining lymph nodes of 
infected animals were found in dendritic cells and (2) that pres-
ence of MTB in dendritic cells and subsequent presentation 
of antigen to CD4+ T cells was critical for the development of 
protective immune responses [43]. The latency-associated MTB 
proteins Hip1 (hydrolase important for pathogenesis 1, a cell 
envelope-associated serine hydrolase) and Acr1 (α-crystallin 1, 
a small heat shock protein) have both been shown to impair 
dendritic cell function [44, 45]: tuning down of dendritic cell 
function by latent MTB could therefore facilitate bacterial per-
sistence during LTBI. Monocyte-derived inflammatory den-
dritic cells are the dominant dendritic cell type in the chronic 
granuloma [46]: they are more migratory compared with mac-
rophages, and they are more efficient in transporting antigens 
to lymph node T cells [47]. Mycobacterium tuberculosis might 
therefore exploit the migratory capacity of dendritic cells to 
promote dissemination during latency. However, the role of 
dendritic cell carriage of MTB in long-term persistence remains 
unclear.
Neutrophils
Neutrophils are among the first phagocytic cells at the site of 
MTB infection and are present in granulomatous lesions during 
both acute and chronic TB in mouse models [48, 49]. They have 
been shown to transport live mycobacteria from peripheral tis-
sue to lymphoid organs in mice, surviving longer and having 
increased capacity for migration when harboring intracellular 
mycobacteria [50]. Mycobacterium tuberculosis inhibits neutro-
phil apoptosis, and abrogation of this effect by deletion of the 
MTB NuoG gene (which encodes a subunit mycobacterial type 
I NADH dehydrogenase complex) increases apoptosis of MTB-
infected neutrophils with subsequent cross-priming to den-
dritic cells and accelerated CD4+ T-cell priming [51]. Because 
neutrophils are ultimately short-lived—even with increases in 
lifespan induced by mycobacterial infection [52]—it appears 
unlikely that they represent a niche for MTB carriage in LTBI. 
More probably, they are harnessed by mycobacteria for early 
dissemination.
OTHER INTRACELLULAR NICHES
The principal line of evidence implicating nonmyeloid cells as 
potential niches for MTB during latent infection comes from 3 
studies mentioned above that used PCR to detect MTB DNA in 
necropsy samples from individuals who had died from causes 
other than TB. Hernández-Pando et al [4] detected MTB DNA 
in sections of macroscopically normal lung tissue from 5 of 
13 such individuals from Ethiopia and 10 of 34 from Mexico. 
Positive cells included alveolar and interstitial macrophages, 
type II pneumocytes, endothelial cells, and fibroblasts. Neyrolles 
et al [5] detected MTB DNA in perinephric, perigastric, pericar-
dial, and subcutaneous adipose tissue in 6 of 19 individuals from 
Mexico and 6 of 20 individuals from France. Barrios-Payán et al 
[6] studied 49 individuals in Mexico, and detected MTB DNA 
in the lung (36 of 49 individuals), the spleen (35 of 49), the kid-
ney (34 of 49), and the liver (33 of 49). Affected cells included 
endothelium, pneumocytes, and macrophages from the lung, 
Bowman’s parietal cells, and convoluted proximal tubules from 
the kidney, macrophages, and sinusoidal endothelial cells from 
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the spleen, and Kupffer cells and sinusoidal endothelium in the 
liver. It should be noted that MTB in these cells was noncultiva-
ble and therefore unlikely to fulfill Koch’s postulates. Although 
nonreplicating MTB has been shown to express 16S ribosomal 
ribonucleic acid and latency-associated genes encoding isoci-
trate lyase and α-crystallin [53, 54], evidence is lacking to show 
that nonreplicating organisms can be resuscitated to cause 
active disease. The uncoupling of the presence of MTB versus 
its ability to cause active disease represents a significant chal-
lenge for contextualization of these findings for LTBI. However, 
data from tissue culture studies and animal models provide 
additional evidence that specific nonmyeloid cells may act as 
niches for MTB during latent infection. These nonprofessional 
phagocytic cells are particularly well suited as niches for MTB 
persistence because they can provide a conducive and protec-
tive intracellular environment that enables them to evade rec-
ognition by the host immune system.
Respiratory Epithelial Cells
Mycobacterium tuberculosis has been shown to invade type II 
alveolar epithelial cells by utilizing heparin-binding hemagglu-
tinin, TLRs, and surfactant proteins [55], and to exhibit a dis-
tinct transcriptional profile while replicating within them, with 
upregulation of genes encoding virulence factors and downreg-
ulation of hypoxia-induced genes [56]. Using a murine chronic 
infection model, Rivas-Santiago et al [57] showed (1) that cili-
ated and nonciliated bronchial epithelial cells could be infected 
by MTB and (2) that these cells produced higher levels of the 
antimicrobial peptide β-defensin than macrophages in response 
to infection. These findings are consistent with results from 
experiments conducted by the same group in a human lung 
epithelial cell line, in which control of MTB growth by alveo-
lar epithelial cells was associated with induction of β-defensin 
expression by lipoarabinomannan, a component of the MTB 
cell wall [58]. The authors of these studies hypothesized that 
β-defensins could exert bacteriostatic effects on MTB within 
respiratory epithelial cells to limit bacillary proliferation and 
induce dormancy. Using a 2-layer Transwell system, Bermudez 
et al [59] found that replication of MTB within a type II alveolar 
cell line enhanced its ability to subsequently invade endothelial 
cells. Moreover, they showed (1) that MTB-infected monocytes 
could translocate across a bicellular layer of epithelial and endo-
thelial cells and (2) that this process was more efficient when the 
epithelial cells were themselves infected with MTB [59]. Taken 
together, these studies indicate that alveolar epithelial cells rep-
resent a conducive environment for MTB persistence as well as 
a niche from which MTB can expand and disseminate from the 
lung before elicitation of adaptive immune responses.
Fibroblasts
Mycobacterium tuberculosis can infect and replicate in fibro-
blasts, which are able to present antigen from heat-killed MTB 
via major histocompatibility complex-II [60]. Fibroblasts 
potentiate bactericidal effects in both nonactivated and acti-
vated macrophages through increased nitrite production; these 
effects are more pronounced when fibroblasts themselves are 
coinfected with MTB [61]. These findings point to an active 
role of fibroblasts in protection within granulomas; however, 
carriage of MTB within fibroblasts during LTBI remains in 
question.
Lymphatic Endothelial Cells
Mycobacterium tuberculosis disseminates from the lungs to 
extrapulmonary sites via lymphatic and circulatory systems. 
Lymph nodes are the most common sites for extrapulmonary 
TB, with viable bacilli often recovered from these sites [62]. 
Mycobacterium tuberculosis has been shown to infect lymphatic 
endothelial cells and to egress to the cell cytosol using MTB 
cell wall phthiocerol dimycocerosates to lyse autophagosomes 
[63]. When activated by interferon-γ, lymphatic endothelial 
cells use autophagy and nitric oxide to kill intracellular bacte-
ria. However, when inactivated, they can support MTB growth 
and persistence [64].
Adipocytes
Neyrolles et  al [5] showed that MTB infects adipocytes via 
scavenger receptors, with intracellular bacilli observed within 
membrane-bound vacuoles. Intracellular MTB accumulated 
in cytoplasmic lipid droplets, with this effect becoming more 
pronounced in mature adipocytes. Furthermore, intracellular 
MTB was shown to replicate in fibroblast-like preadipocytes, 
with replication decreasing as preadipocytes differentiated into 
mature adipocytes [5]. Other investigators have reported that 
infection of adipose tissue by MTB is accompanied by infiltra-
tion of natural killer cells and MTB-specific CD8+ T cells and 
upregulation of tumor necrosis factor, interleukin (IL)-6, adi-
ponectin, and IL-10 [65, 66]. In contrast to many of the cell 
phenotypes thus far considered as intracellular niches for LTBI, 
adipocytes are relatively long-lived in the host, with a life span 
of 8 years or more [67].
Stem Cells
Recent studies have shown that both mesenchymal and hema-
topoietic stem cells recovered from individuals with LTBI or 
having successfully received chemotherapeutic treatment for 
active TB contained intracellular MTB in a predominantly 
uncultivable form. The hypoxic environment of the bone mar-
row [68, 69], expression of active drug efflux pumps by bone 
marrow stem cells, and the lack of intracellular antibacterial 
mechanisms in early-stage stem cells [70, 71] all conspire to 
make bone marrow stem cells an attractive potential niche for 
carriage of MTB during latent infection. Das et al [7] showed 
(1) that mesenchymal stem cells from healthy volunteers 
were preferentially infected by virulent MTB in vitro and (2) 
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that viability of MTB dropped 4-fold when the mesenchymal 
stem cells lost their CD271/CD133 markers, indicating that 
the undifferentiated mesenchymal stem cell state favors per-
sistence of infection. Mycobacterium tuberculosis infected the 
CD271+ bone marrow mesenchymal stem cells via scavenger 
receptors MARCO and SR-B1, and mesenchymal stem cells 
controlled intracellular MTB using autophagic mechanisms 
[72]. Mesenchymal stem cells killed avirulent mycobacteria 
but not MTB via modulation of cathelicidin expression [73]. 
Moreover, CD271+ bone marrow mesenchymal stem cells 
harboring MTB are localized in the hypoxic niche in both 
mice and humans, a critical microenvironmental factor that 
is known to induce dormancy [74]. The ability of mesenchy-
mal stem cells to maintain MTB depends on the inflamma-
tory milieu: Yang et al [75] reported that murine macrophages 
produced cytokines during mycobacterial infection that pro-
moted clearance of MTB from mesenchymal stem cells by 
increasing production of nitric oxide in an IL-1β-dependent 
manner.
Tornack et  al [10] reported that human peripheral blood 
long-term pluripotent hematopoietic stem cells harvested 
from IGRA-positive asymptomatic individuals contained MTB 
DNA, whereas those from IGRA-negative individuals did 
not. Mycobacterium tuberculosis within long-term pluripotent 
hematopoietic stem cells expressed dormancy genes and did 
not form colonies on agar but were resuscitated when admin-
istered intratracheally to immune-deficient Rag-/-IL2Rγ-/- mice 
to form nascent lung granulomas accompanied by detection of 
cultivable MTB. Using a murine infection model, Reece et  al 
[9] showed that hematopoietic stem and progenitor cells con-
taining noncultivable MTB propagated canonical hallmarks 
of TB when transferred to recipient naive mice, provided that 
both donor and recipient mice were unable to express inducible 
nitric oxide synthase 2. Nitric oxide synthase 2 mediates killing 
of intracellular bacteria via production of nitric oxide, a key 
protective mechanism against TB in mice. Nitric oxide synthase 
2 is not expressed in nondifferentiated hematopoietic stem cells, 
and hence MTB could remain viable in them [76].
Both mesenchymal and hematopoietic stem cells are highly 
mobile, and they transition between the bone marrow, the 
circulation, and TB granulomas [77]. In Figure  1, we illus-
trate the hypothesis that stem cells containing dormant MTB 
could therefore seed new infectious foci in peripheral tissues. 
It is intriguing that almost all the cell types discussed in our 
review as potentially harboring MTB can differentiate from 
progenitor states of either mesenchymal or hematopoietic 
stem cells (the exception being tissue-resident macrophage 
lineages, which are seeded during waves of embryonic hema-
topoiesis and self-maintained independent of contribution 
from the bone marrow during adulthood [78]). This obser-
vation raises the possibility that MTB in differentiated cells 
within the tissues could originate from a precursor stem cell 
that already contained MTB. The fact that hematopoietic 
stem and progenitor cells harboring MTB from both experi-
mentally infected mice and humans with LTBI can propagate 
TB after adoptive transfer of cells in mouse models represents 
an important starting point in testing this hypothesis. Further 
investigation is needed to track the developmental states of 
the transferred cells harboring MTB as infection develops. 
In considering this hypothesis, we raise 2 important caveats. 
First, we do not exclude the probability that some nonmy-
eloid cell types (particularly epithelial and endothelial cells) 
may become infected directly as well as or instead of via a 
stem cell route. Second, we acknowledge that these niches 
are unlikely to be specific to the context of latent infection, 
and that infection of all of these different cell types may also 
occur during active TB, which typically arises within 2 years 
of exposure to an infectious case [79].
Bone marrow Granuloma
MSC
HSC
A B C D E MTBMTB
Bone marrow
Endothelial cell
Fibroblast
Adipocyte
Epithelial cell
Figure 1. Hypothesis: bone marrow stem cells seed Mycobacterium tuberculosis infection to the periphery. (A) Uninfected mesenchymal stem cells (MSC) and hematopoi-
etic stem cells (HSC) enter the circulation from the bone marrow. (B) The cells migrate to, and are incorporated into, the granuloma where they are infected with M tuber-
culosis (red bars). (C) Infected MSC and HSC return to the bone marrow to establish a niche of M tuberculosis infection during latency. (D) Infected stem cells propagate M 
tuberculosis infection to the periphery. (E) Mycobacterium tuberculosis may also infect nonmyeloid cells directly, eg, via the airway or by hematogenous or lymphatic spread.
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CONCLUSIONS
The presence of MTB in diverse nonphagocytic cells of 
latently infected individuals has been recognized for almost 
20  years, but the route by which the bacillus reaches these 
sites has not been apparent. Recent discoveries implicat-
ing hematopoietic and mesenchymal stem cells as poten-
tial niches for MTB raise the possibility that stem cells may 
disseminate infection, leading to the wide anatomical and 
cellular distribution of MTB reported in latently infected 
individuals. Understanding the role of both hematopoietic 
and mesenchymal stem cells in the maintenance of latent 
MTB infection and triggering of active TB disease remains 
an exciting area of investigation.
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